Open Access · CC BY 4.0
Retraction: Cimifugin suppresses NF-κB signaling to prevent osteoclastogenesis and periprosthetic osteolysis
Frontiers in Pharmacology · 11.11.2026 · 17
DOI: 10.3389/fphar.2026.2021925 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 11.11.2026. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). Retraction: Cimifugin suppresses NF-κB signaling to prevent osteoclastogenesis and periprosthetic osteolysis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.2021925
Vancouver
Retraction: Cimifugin suppresses NF-κB signaling to prevent osteoclastogenesis and periprosthetic osteolysis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.2021925
BibTeX
@article{euvimed2026,
title = {Retraction: Cimifugin suppresses NF-κB signaling to prevent osteoclastogenesis and periprosthetic osteolysis},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.2021925}
}
EUVIMED